Leal Therapeutics

Leal Therapeutics announced $30M in Series A Extension financing on August 17, 2026. Leal Therapeutics raised a $30 million second close of its Series A, including new investor Eli Lilly, to advance LTX-001 in schizophrenia and LTX-002 in ALS.

Round details

The financing includes backing from Eli Lilly and Company, OrbiMed, Newpath Partners, Euclidean Capital, SV Health Investors’ Dementia Discovery Fund, Chugai Venture Fund, Alexandria Venture Investments, PhiFund. The company did not publish a valuation with the announcement.

• Round: Series A Extension
• Capital announced: $30M
• Headquarters: Worcester, MA

How the company plans to use the capital

Leal said proceeds from the second closing will advance LTX-001 through an initial readout of its Phase 1b/2a schizophrenia trial and progress LTX-002 through additional dosing cohorts in its ongoing Phase 1/2 ALS trial.

Why this matters for GTM teams

The second close added Eli Lilly and Company as a new investor alongside existing investors including OrbiMed, Newpath Partners and Chugai Venture Fund.

Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.

Source and methodology

This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.

Primary source: Leal Therapeutics Series A extension announcement.